Chester County News and Community Website
NEWTOWN SQUARE, PA — ArriVent BioPharma, Inc. (Nasdaq: AVBP) has announced the appointment of Merdad Parsey, M.D., Ph.D., to its Board of Directors. A respected leader in global clinical development, …
ArriVent BioPharma Appoints Dr. Merdad Parsey to Board of Directors Read More NEWTOWN SQUARE, PA — ArriVent BioPharma, Inc. (NASDAQ: AVBP) announced its 2024 financial results, showcasing significant progress in clinical programs and pipeline expansion. The company highlighted substantial milestones achieved over …
ArriVent BioPharma Reports 2024 Financial Results and Key Achievements Read More NEWTOWN SQUARE, PA and SHANGHAI, CHINA — ArriVent BioPharma, Inc. (Nasdaq: AVBP) has announced an exclusive license agreement with Lepu Biopharma Co., Ltd. (Stock Code: 02157.HK) for global rights outside Greater …
ArriVent BioPharma Secures Global Rights to MRG007 in Strategic Deal with Lepu Biopharma Read More NEWTOWN SQUARE, PA — ArriVent BioPharma, Inc. (Nasdaq: AVBP) has announced its financial results for the third quarter of 2024, alongside significant progress in its lead program for firmonertinib, a …
ArriVent BioPharma Reports Advancements and Q3 2024 Financial Results Read More NEWTOWN SQUARE, PA — ArriVent BioPharma, Inc. (Nasdaq: AVBP) has announced encouraging interim results from its global Phase 1b FURTHER trial, presented at the prestigious IASCLC 2024 World Conference on Lung …
ArriVent BioPharma Unveils Promising Phase 1b Data for Firmonertinib in Treating NSCLC Read More NEWTOWN SQUARE, PA — ArriVent BioPharma, Inc. (Nasdaq: AVBP) has announced its financial results for the second quarter of 2024, alongside significant advancements in its oncology pipeline and recent corporate …
ArriVent BioPharma Reports Strong Second Quarter and Highlights Progress Read More NEWTOWN SQUARE, PA — ArriVent BioPharma, Inc. (Nasdaq: AVBP) has announced that it will present significant interim findings from its randomized Phase 1b FURTHER study on firmonertinib monotherapy. This presentation …
ArriVent BioPharma to Present Groundbreaking Data at 2024 World Conference on Lung Cancer Read More SUZHOU, China and NEWTOWN SQUARE, PA — ArriVent BioPharma, Inc. announced a strategic collaboration with Jiangsu Alphamab Biopharmaceuticals Co., Ltd. (“Alphamab”) to develop and commercialize novel antibody drug conjugates (ADCs) …
ArriVent BioPharma Partners with Alphamab to Develop Cutting-Edge Cancer Treatments Read More NEWTON SQUARE, PA — ArriVent BioPharma, Inc. announced the appointment of Dr. John Hohneker to its Board of Directors. With over three decades of experience in leading biopharmaceutical ventures and …
ArriVent BioPharma Bolsters Board with Biopharmaceutical Expert Dr. John Hohneker Read More NEWTOWN SQUARE, PA — ArriVent BioPharma, Inc. (Nasdaq: AVBP) has announced positive strides in its first-quarter progress, particularly in the development of firmonertinib, a promising drug for non-small cell lung …
ArriVent BioPharma Advances in Lung Cancer Research, Sets Sights on Future Milestones Read More